World Rheumatoid Arthritis (RA) Disease Analysis and Market Report 2020-2025: Spearheaded by Humira and Enbrel, the anti-TNF Class will Remain Dominant, Despite Pressure from Biosimilars - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Disease Analysis: Rheumatoid Arthritis" report has been added to ResearchAndMarkets.com's offering.

The rheumatoid arthritis (RA) market will decline slightly over the 2020-29 forecast period, with sales in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) ending at $19.2bn in 2029, and decreasing at an overall compound annual growth rate (CAGR) of -0.6%. Revenues in this market will peak at $22.3bn in 2025 due to increasing disease prevalence, uptake of new targeted drugs, and the anticipated launch of pipeline drugs, before decreasing as a whole due to biosimilar and generic erosion.

Latest Key Takeaways

• The rheumatoid arthritis (RA) market is set to experience increasing attrition due to biosimilar competition. The EU market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance of biosimilars compared to other countries. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence builds, with long-term data supporting biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars and encourage uptake.
• Nevertheless, as the RA caseload enlarges and several pipeline drugs launch, this will provide impetus for market growth. The publisher estimates that in 2018, there were 25.9 million prevalent cases of RA worldwide, and expects that number to increase to 28.6 million prevalent cases by 2027.
• As multi-billion-dollar products, Humira and Enbrel represent the best-selling brands in the market, and their stronghold will continue. In the US, biosimilars will face challenges in usurping branded anti-TNF drugs, with adalimumab biosimilars not expected to enter until 2023, etanercept biosimilars held in patent litigation, substantial originator rebates, and exclusive contracting with payers.
• Gilead's Jyseleca is the latest addition to the oral JAK inhibitor class, following Rinvoq's US launch in September 2019. AbbVie is positioning Rinvoq as a follow-on product from Humira, supported by an extensive global pivotal trial program, and AbbVie has demonstrated Rinvoq's superiority in head-to-head trials with gold-standard Humira. AbbVie's experience and presence in the RA market will foster success for the drug, despite its third-to-market status.
• Although the JAK inhibitors are differentiated by their convenient oral administration, the class has been associated with venous thromboembolic event (VTE) concerns, and this stigma may fuel hesitancies towards using these products. Despite AbbVie releasing data showing that the rate of VTEs associated with Rinvoq treatment was in line with the background rate for RA patients, the FDA included a black box warning for the safety issue. Furthermore, the drugs are premium-priced, and the entry of generic tofacitinib will not only erode market share from Xeljanz, but also from Olumiant, Rinvoq, and Jyseleca.

Key Topics Covered:

OVERVIEW

• Latest key takeaways

DISEASE BACKGROUND

• Definition
• Patient segmentation

TREATMENT

• ACR treatment guidelines
• EULAR treatment guidelines

EPIDEMIOLOGY

• Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

• Shaking Off US Rebuff, Gilead And Galapagos Get Filgotinib Green Lights In EU And Japan
• Cadila Pharma Adds To Indian Biosimilars With Adalimumab
• Lupin And Mylan Launch Etanercept In Germany
• Gilead's RA Hopeful Filgotinib Hit By Complete Response Letter
• Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India
• FDA Approves Mylan's Humira Biosimilar
• Japan Approves First Humira Biosimilar
• Sandoz' Ziextenzo And Riximyo Cleared In Canada
• Teva And Celltrion Gain Arthritis Advantage On Rituximab
• Pfizer Has Eyes On EU Rituximab Market Following EC Approval
• Mylan And Lupin Get EU Etanercept Nod
• Celltrion Eyes 'Competitive Edge' With Adalimumab Filing
• Celltrion Launches Remsima SC In UK
• Pfizer's Ruxience Rituximab Biosimilar Gets CHMP Nod
• Pfizer Will Not Launch EU Adalimumab
• EU Approvals: Rinvoq Cleared For RA
• CHMP Positive On Pfizer's Adalimumab
• Amgen Gets US Infliximab Nod

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Jubilant Obtains Americas Rights To Navidea's RA Diagnostic Agent
• Beximco And Mylan Strike Biosimilars Deal
• Mundipharma Will Sell Samsung Bioepis' Biosimilars In Taiwan, Hong Kong
• Deals Shaping The Medical Industry, January 2020

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase
• Recent Events

DRUG ASSESSMENT MODEL

• Biologic DMARDs
• Non-biologic DMARDs

MARKET DYNAMICS

FUTURE TRENDS

• Brands will face headwinds as the RA market is penetrated by more biosimilars
• Spearheaded by Humira and Enbrel, the anti-TNF class will remain dominant, despite pressure from biosimilars
• Expansion of the JAK inhibitor class will be dampened by the entry of generic tofacitinib and safety concerns
• New pipeline products will be relegated to later lines of therapy

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

• Piclidenoson for Rheumatoid Arthritis (October 6, 2020)
• Jyseleca for Rheumatoid Arthritis (August 18, 2020)
• ABBV-3373 for Rheumatoid Arthritis (June 10, 2020)
• Rinvoq for Rheumatoid Arthritis (June 6, 2020)
• Multiple Drugs for Rheumatoid Arthritis (June 25, 2019)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

• Therapies are clinically comparable
• Pricing and insurance coverage drive prescribing

UNMET NEEDS

• There is critical unmet need for effective drugs that achieve remission
• Unmet need exists for targeted treatments applied with a stratified medicine approach
• With RA patients being treated with costly specialty drugs, more affordable treatments are needed
• Better tolerated, safer drugs are desired

BIBLIOGRAPHY

• Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/er1jy5